Vaxcyte Income Statement (2019-2026) | PCVX

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
52.59M53.03M56.50M58.62M60.57M64.88M80.64M93.81M95.10M95.36M108.76M110.58M124.43M124.89M128.94M129.82M130.03M131.06M144.31M144.79M
Operating items
Research & Development (Quarter)
20.43M23.07M31.68M38.47M47.68M51.63M58.08M72.69M97.42M104.15M94.59M131.51M116.94M133.61M148.13M194.18M209.93M242.06M312.78M267.85M
Selling, General & Administrative (Quarter)
6.52M6.77M7.54M9.42M10.90M11.95M13.11M14.46M15.61M17.53M19.89M21.47M22.99M28.55M32.66M32.04M32.45M32.22M33.07M34.92M
Other Operating Expenses (Quarter)
23.00M75.00M
Operating Expenses (Quarter)
26.95M29.85M39.22M47.89M58.58M86.57M71.19M87.15M113.03M196.68M114.47M152.98M139.92M162.17M180.79M226.22M242.38M274.28M345.85M302.78M
Operating Income (Quarter)
-26.95M-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M-302.78M
EBIT (Quarter)
-26.95M-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M-302.78M
Non-operating items
Non Operating Investment Income (Quarter)
0.02M0.03M0.00M
Interest & Investment Income (Quarter)
0.09M0.10M-0.59M0.40M1.19M6.63M10.39M16.45M18.50M17.57M21.67M23.81M28.06M36.46M32.94M31.07M29.26M26.45M26.61M25.75M
Other Non Operating Income (Quarter)
-0.05M1.28M0.23M-1.73M-0.69M8.52M10.73M18.81M20.36M-47.03M-2.21M0.47M8.74M-11.37M7.14M28.57M0.29M1.32M-1.38M-7.28M
Non Operating Income (Quarter)
19.45M24.28M36.80M25.09M40.08M59.65M29.55M27.78M25.23M18.48M
Net income details
EBT (Quarter)
-120.32M-29.75M-118.57M-113.54M-131.53M-79.94M-207.78M-316.10M-343.44M-179.11M-455.93M-133.95M-115.48M-117.31M-150.94M-316.12M-331.15M-378.18M-322.95M-477.96M
Profit After Tax (Quarter)
-26.61M-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M-92.66M-180.80M-95.02M-128.70M-103.12M-141.09M-140.72M-166.57M-212.83M-246.51M-320.62M-285.01M
Income from Continuing Operations (Quarter)
-120.32M-29.75M-118.57M-113.54M-131.53M-79.94M-207.78M-316.10M-343.44M-179.11M-455.93M-133.95M-115.48M-117.31M-150.94M-316.12M-331.15M-378.18M-322.95M-477.96M
Consolidated Net Income (Quarter)
-120.32M-29.75M-118.57M-113.54M-131.53M-79.94M-207.78M-316.10M-343.44M-179.11M-455.93M-133.95M-115.48M-117.31M-150.94M-316.12M-331.15M-378.18M-322.95M-477.96M
Income towards Parent Company (Quarter)
-120.32M-29.75M-118.57M-113.54M-131.53M-79.94M-207.78M-316.10M-343.44M-179.11M-455.93M-133.95M-115.48M-117.31M-150.94M-316.12M-331.15M-378.18M-322.95M-477.96M
Net Income towards Common Stockholders (Quarter)
-26.61M-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M92.66M-623.73M-455.93M-133.95M-115.48M-117.31M-150.94M-316.12M-331.15M-378.18M-322.95M-477.96M
Additional items
EPS (Basic) (Quarter)
-0.51-0.55-0.68-0.80-0.93-1.20-0.70-0.700.91-6.42-4.08-1.14-0.93-0.96-1.11-2.32-2.43-2.78-2.31-3.31
EPS (Diluted) (Quarter)
-0.51-0.55-0.68-0.80-0.93-1.20-0.70-0.700.91-6.42-4.08-1.14-0.93-0.96-1.11-2.32-2.43-2.78-2.31-3.31
Shares Outstanding (Quarter)
52.19M51.92M57.55M60.82M61.99M64.88M86.21M98.06M101.67M97.16M111.69M117.26M123.69M122.00M135.69M136.03M136.20M136.09M139.51M144.49M
Shares Outstanding (Diluted) (Quarter)
52.19M51.92M57.55M60.82M61.99M64.88M86.21M98.06M101.67M97.16M111.69M117.26M123.69M122.00M135.69M136.03M136.20M136.09M139.51M144.49M
EBITDA (Quarter)
-26.95M-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M-302.78M
Interest Expenses (Quarter)
93.46M78.76M66.05M74.14M146.99M245.41M248.91M363.12M4.78M3.61M-8.41M3.08M120.97M118.03M130.35M3.71M200.93M